Dr. Parjeet Kaur

Associate Director

23 years of experience

Endocrinologist

MBBS, MD, DM

Reg. No.:6788, Haryana State Medical Council

Medanta - The Medicity Hospital, Gurgaon

English, Hindi

Consultation Fee ₹ 1800

Book an Appointment

About Dr. Parjeet Kaur

Dr. Parjeet Kaur is a highly skilled Endocrinologist & Diabetologist with over 23 years of experience.
She specializes in a wide range of conditions, including Type 2 Diabetes, Type 1 Diabetes, Obesity, Thyroid Disorders, Hyperparathyroidism, Growth and Pubertal Disorders, Osteoporosis, PCOS, Adrenal Disorders, and Pituitary Disorders.
She possesses extensive experience in managing Inpatient Hyperglycemia and providing diabetes care to patients post-CABG, Renal, and Liver Transplant.
Her educational qualifications include MBBS from the University of Delhi, 2001, MD (Medicine) from All India Institute of Medical Sciences, New Delhi, 2005, and DM (Endocrinology) from All India Institute of Medical Sciences (AIIMS), New Delhi, 2011.
She has honed her expertise in Endocrinology through positions at Mayo Clinic, USA, and AIIMS, New Delhi.
Dr. Parjeet Kaur actively contributes to various academic and educational programs, including the DNB Endocrinology program, Type 1 Diabetes public awareness initiatives, and diabetes educators training.
Additionally, she engages in research endeavors and frequently participates in national and international Endocrinology conferences, boasting multiple publications in indexed journals.
She is an active member of the Medical Council of India (MCI).

Education

MBBS, University of Delhi, 2001
MD (Medicine), All India Institute of Medical Sciences (AIIMS), New Delhi, 2005
DM (Endocrinology), All India Institute of Medical Sciences (AIIMS), New Delhi, 2011

Past Experience

Senior Consultant, All India Institute of Medical Sciences (AIIMS), New Delhi

Awards

Golden Aim Women Healthcare Leader Award: Diabetology, 2022
Silver Medal ISBMR, 2018
A V Gandhi Award for Excellence in Endocrinology, 2011
MMS Ahuja Award For Best DM (Endocrinology) resident (AIIMS), 2011

Associations/Membership

Medical Council of India (MCI)

Paper Published

Dapagliflozin for inpatient hyperglycemia in cardiac surgery patients with type 2 diabetes: randomised controlled trial (Dapa-Hospital trial), 2023
Efficacy and safety of degludec U100 versus glargine U300 for the early postoperative management of patients with type 2 diabetes mellitus undergoing coronary artery bypass graft surgery: A non?inferiority randomized trial, 2022
LBSUN207 Efficacy And Safety Of Degludec U100 Versus Glargine U300 For The Hospital Management Of Patients With Type 2 Diabetes: A Prospective, Open-label, Non-inferiority Randomized Controlled Trial, 2022
Non-alcoholic fatty liver disease-related fibrosis and sarcopenia: An altered liver-muscle crosstalk leading to increased mortality risk, 2022
Efficacy and Safety of Degludec U100 Versus Glargine U300 for the Hospital Management of Patients with Type 2 Diabetes: A Prospective, Open-Label, Non-Inferiority Randomized Trial, 2022
Denosumab can be used successfully as a bridge to surgery in patients with severe hypercalcemia due to primary hyperparathyroidism, 2021
Prevalence of clinically relevant liver fibrosis due to non-alcoholic fatty liver disease in Indian individuals with type 2 diabetes, 2021
Decreased handgrip strength in patients with type 2 diabetes: A cross-sectional study in a tertiary care hospital in north India, 2021
Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial), 2020
1457-P: Clinical, Biochemical, and Genetic Profile of Patients with Young-Onset Diabetes in North India, 2020
To Establish the True Positive Percentage of Cases Where Ultrasound Detected Nodules in Sestamibi Negative Cases of Hyperparathyroidism. Retrospective Data from A Single Institution", 2017Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial), 2018
Effect of two different doses of oral cholecalciferol supplementation on serum 25-hydroxy-vitamin D levels in healthy Indian postmenopausal women: A randomized controlled trial, 2013
Osteoporosis in Asia: A Call to Action, 2012